DE69835886D1 - Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung - Google Patents

Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung

Info

Publication number
DE69835886D1
DE69835886D1 DE69835886T DE69835886T DE69835886D1 DE 69835886 D1 DE69835886 D1 DE 69835886D1 DE 69835886 T DE69835886 T DE 69835886T DE 69835886 T DE69835886 T DE 69835886T DE 69835886 D1 DE69835886 D1 DE 69835886D1
Authority
DE
Germany
Prior art keywords
protein kinase
paclitaxol
combination
modified protein
specific hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835886T
Other languages
English (en)
Inventor
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69835886D1 publication Critical patent/DE69835886D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69835886T 1997-03-12 1998-02-12 Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung Expired - Lifetime DE69835886D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4074097P 1997-03-12 1997-03-12
PCT/US1998/003003 WO1998040479A1 (en) 1997-03-12 1998-02-12 Modified protein kinase a-specific oligonucleotides and methods of their use

Publications (1)

Publication Number Publication Date
DE69835886D1 true DE69835886D1 (de) 2006-10-26

Family

ID=21912675

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835886T Expired - Lifetime DE69835886D1 (de) 1997-03-12 1998-02-12 Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung

Country Status (7)

Country Link
EP (1) EP1007656B1 (de)
JP (1) JP2002501370A (de)
AT (1) ATE339498T1 (de)
AU (1) AU6328598A (de)
CA (1) CA2283626A1 (de)
DE (1) DE69835886D1 (de)
WO (1) WO1998040479A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1316607A1 (de) * 1999-03-31 2003-06-04 Hybridon, Inc. Pseudo-zyklische Oligonukleobasen zur Hemmung des Tumorwachstums

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
AU6527094A (en) * 1993-03-31 1994-10-24 Hybridon, Inc. Modified oligonucleotides having improved anti-influenza activity
JPH1135595A (ja) * 1994-12-02 1999-02-09 Pola Chem Ind Inc アンチセンスオリゴヌクレオチド及びそれを用いた制癌剤
WO1996031600A1 (en) * 1995-04-03 1996-10-10 Hybridon, Inc. Method of modulating gene expression without depleting complement
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide
US7074768B2 (en) * 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use

Also Published As

Publication number Publication date
AU6328598A (en) 1998-09-29
EP1007656B1 (de) 2006-09-13
CA2283626A1 (en) 1998-09-17
ATE339498T1 (de) 2006-10-15
WO1998040479A1 (en) 1998-09-17
JP2002501370A (ja) 2002-01-15
EP1007656A1 (de) 2000-06-14

Similar Documents

Publication Publication Date Title
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
FI951612A (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
DE69808274D1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
WO2002006316A3 (en) Alpha-msh related compounds and methods of use
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
EP0691980A1 (de) 7-deazapurin modifizierte oligonukleotide
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
AU7241296A (en) Modified protein kinase a-specific oligonucleotides and methods of their use
WO1998006841A3 (en) Two human nsp-like proteins
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DE69826493D1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
DE68901878D1 (de) Verfahren zur faerbung von nichtradioaktiven markierten nukleinsaeuren und zusammensetzung zum gebrauch in diesem verfahren.
MX9703364A (es) Peptidos capaces de unirse al dominio sh3 de la proteina gap, secuencias nucleotidicas que codifican para estos peptidos, su preparacion y su uso.
DE69835886D1 (de) Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung
WO1999066051A3 (en) Nek-related and bub1-related protein kinases
EP1248635A4 (de) Antisense-modulation der glykogen-synthase-kinase-3alpha-expression
DE69730967D1 (en) Human dnase ii
DE69529235D1 (de) Menschliche dnase i varianten
WO2002024864A3 (en) Antisense modulation of syntaxin 4 interacting protein expression
WO2002055659A3 (en) Antisense modulation of integrin beta 4 binding protein expression
ATE65543T1 (de) Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
MX9706429A (es) Variantes de dnasa i humana.

Legal Events

Date Code Title Description
8332 No legal effect for de